Participants, Interventions And Outcomes
Study setting {9}
Patients from 9 academic hospitals in Austria and Germany will be eligible for enrolment. A list of study sites can be obtained on request from the Sponsor.
Eligibility criteria {10}
Inclusion criteria
The study will enroll patients with pulmonary permeability edema (EVLWI ≥ 10 ml/kg PBW) and moderate to severe ARDS admitted to an Intensive Care Unit and under mechanical ventilation. To be eligible to participate in this study, an individual must meet all the following criteria:
1. Informed consent
2. Male or female ≥18 years of age.
3. Patient has been admitted to an ICU, is mechanically ventilated and stable in this condition for at least 8 hours.
4. Moderate-to-severe ARDS diagnosis as defined by the Berlin Definition:
- Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms.
- Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.
- Respiratory failure not fully explained by cardiac failure or fluid overload (origin of edema).
- PaO2/FiO2 ≤ 200 mm Hg with Positive End-Expiratory Pressure (PEEP) ≥5 cm H2O.
5. Verified ARDS diagnosis (moderate or severe according to Berlin Definition) not older than 48 hours.
6. Extravascular lung water index (EVLWI) ≥ 10 ml/kg PBW as assessed with a validated bedside measurement (single indicator transpulmonary thermodilution measurement, such as with PiCCO® from Pulsion or VolumeView from Edwards).
7. Patient who meets criteria for extensive hemodynamic monitoring as per international intensive care medicine standards.
Exclusion criteria
Patients must meet none of the exclusion criteria listed below.
1. History of clinically relevant allergies or idiosyncrasies to solnatide.
2. Known use of any other investigational or non-registered drug within 30 days or within 5 half-lives of these drugs prior to study enrolment, whichever is longer. No exceptions are allowed in this study.
3. Severe state of septic shock with a Mean Arterial Pressure (MAP) ≤ 65 mmHg and a serum lactate level > 4 mmol/L (36 mg/dl) despite adequate volume resuscitation.
4. An underlying clinical condition that, in the opinion of the Investigator, would make it very unlikely for the patient to be successfully weaned from ventilation due to severe underlying diseases (e.g. severe malnutrition, severe neurological diseases, pulmonary fibrosis or COPD).
5. Extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support. In no way are patients to be denied or delayed these procedures to avoid exclusion from the study.
6. Neutrophil count < 0.3 x 109/L.
7. Cancer treatment (chemotherapy or biological) or therapy with other immunosuppressive agents for organ transplantation within 2 weeks.
8. Cachexia (BMI < 18.5 kg/m2).
9. Unequivocal cases of cardiogenic pulmonary edema (if differential diagnosis based on an ARDS triggering condition and clinical replicability is not possible, echocardiography may be indicated).
10. Severe skin burns involving more than 15% of body surface.
11. Subjects who are extremely unlikely to survive more than 48 hours due to the acute conditions of the patient in the opinion of the Investigator.
12. Subjects transferred from a hospital not participating in this study who are already planned to be re- transferred during the observation period.
13. Subjects who are not expected to survive the next month because of an underlying uncorrectable medical condition or a do not resuscitate order.
14. Women known to be pregnant, women who are lactating, women with a positive or indeterminate pregnancy test, on screening, and males of reproductive potential and women of childbearing potential who are not willing to use highly effective methods of birth control/contraception for a duration defined in the patient’s Informed Consent Form.
Who will take informed consent? {26a}
Informed consent will be taken by appointed investigators, who had been trained beforehand according to GCP standards. Consent forms describing in detail the study intervention, study procedures, and risks are given to the participant/legal representative, and written documentation of informed consent is required.
Since ARDS patients in this study are in the ICU under mechanical ventilation, it is very likely that most will not be able to give their written informed consent prior to enrolment in the study.
According to German Law persons unable to give consent are subject to specific legal regulations and therefore can be included into medical research projects only under strict requirements. To obtain consent the following procedures must be followed:
- In case of an emergency, the investigator has to find out whether a patient’s representative has been appointed by power of attorney for personal care (“Vorsorgevollmacht”). Usually, this will be done by on-site interviewing of accompanying persons of the patient.
- If a patient’s representative appointed by power of attorney for personal care (“Vorsorgevollmacht”) is available, he/she will check whether a patient’s decree (“Patientenverfügung”) exists and whether it is in accordance with the patient’s current living and treatment conditions. If a patient’s decree is available, the patient’s representative will make sure that the patient’s specifications will be implemented. If a patient’s decree is not available or is not in accordance with the specific situation, the patient’s representative is obliged to act according to the presumed patient’s will based upon oral or written statements, values and ethical or religious beliefs of the patient concerned. To determine the presumed will of the patient whether to participate in a clinical study or not, close relatives and other reliable persons might be involved provided that this process does not lead to any delays being in conflict with the urgency of the treatment.
- The information and consent process will be carried out with the patient’s representative in the same way as with the patient. The patient’s representative will sign the consent form on behalf of the patient. If a patient is unable to give consent but still able to follow the information and consent process partially, the patient must also be informed. Even if expressed non-verbally, a patient’s wish either to participate or not to participate in the trial must be respected.
- If a patient’s representative can’t be asked for consent to include the patient in the study, the appointment of a provisional patient’s representative must be made by the local district court (“Amtsgericht”). If, in cases of urgency, such an appointment is not possible, a judge may also take the decision for the benefit of the patient.
- If neither the appointment of a patient’s representative nor a judicial urgent decision is possible in time, § 41 paragraph 1 clause 2 of the German Drug Law is applicable. According to this paragraph, “treatment which is necessary without delay to save the life of the person concerned, restore good health or alleviate suffering, can be dispensed immediately. Consent for continued participation must be obtained as soon as it is possible and reasonable”. In this case, the investigator must consider all known indications regarding the patient's presumed will. It is the responsibility of the investigator to examine whether, in his view, the patient could be included in the clinical trial.
- The process to determine the patient's presumed will to participate in a clinical study will be documented in accordance with local procedures. Once the patient regains his/her ability to consent, he/she shall be asked to give his/her consent to the continuation of the clinical trial.
Additional consent provisions for collection and use of participant data and biological specimens {26b}
Not applicable, biological samples will not be retained after the study is complete.
Interventions
Explanation for the choice of comparators {6b}
This ascending dose study consists in the sequential administration of 5 mg, 60 mg and 125 mg of solnatide.
In cell-based non-clinical pharmacodynamic studies, the EC100 of solnatide-induced ENaC activation was found to be approximately 120 nM. Various models taking into account lung volume, lung weight and lung surface area have indicated that a nebulizer filling dose of 5 mg solnatide corresponds most closely with the non-clinical cell-based experimental setup. A single application of 5 mg solnatide corresponds to the lowest dose of the previous phase I clinical study (EudraCT: 2011-000223-33).
A bridging dose of 60 mg was chosen between the low and high dose. This dose was used in a pharmacological study in pigs and may be effective in a clinical setting also. In addition, this dose corresponds to the intermediate dose level of the previous phase I clinical study (EudraCT: 2011-000223-33).
In previous clinical Phase II trials, patients received two daily doses each of 125 mg solnatide reconstituted in 5 ml water for injection delivered as aerosol via nebulization for up to seven days. This dose level is below the highest dose level used in the previous phase I study (EudraCT: 2011-000223-33). It represents a dose level corresponding to the most effective dose levels used in previous pharmacologic studies and showed promising outcomes in the two previous Phase IIa trials (EudraCT: 2012-001863-64; 2013- 000716-21).
Intervention description {11a}
Active agent
The Investigational Medicinal Product (IMP) is “Solnatide 25 mg powder for reconstitution for solution for inhalation.” The IMP is a sterile lyophilized preparation of the drug substance solnatide, a synthetic peptide composed of 17 naturally occurring amino acids. One N-terminal cysteine and one C-terminal cysteine form an intra-molecular disulphide bridge. Solnatide contains no post-translational modifications.
Solnatide was manufactured, characterized and released based on requirements of the European Pharmacopoeia, European and international quality and safety guidelines including ICH guidelines related to chemical compounds and / or synthetic peptides. Guidelines and regulations related to recombinant proteins do not apply to the development compound.
Prior to clinical use, each vial with the IMP is to be reconstituted with 1 ml of water for injection (commercial product) resulting in a solnatide solution with a concentration of 25 mg/ml. Reconstituted IMP in the required clinical-use concentration is provided as a clear solution in a closed single-use sterile plastic syringe for transportation purpose at 2-8°C for immediate use with the nebulizer Aeroneb Solo.
However, in-use storage time of the reconstituted solution in the single-use plastic syringe may be extended up to three days at 2 to 8°C, if required and a corresponding Manufacturer’s Authorization is in place.
The in-use stability of the reconstituted solution is described in the Investigators Brochure. The chemical and physical in-use stability of the reconstituted solution in the single-use plastic syringe has been demonstrated for 7 days at 2 - 8°C. Sterility of the reconstituted solution in the single-use plastic syringe has been demonstrated after in-use storage times of 4 days at 2 to 8°C provided reconstitution has taken place in controlled aseptic conditions.
Placebo
Commercially available 0.9% saline solution in vials.
Patients will receive 5 ml of the study drug containing 5 mg, 60 mg or 125 mg solnatide or 0.9% saline according to treatment allocation via endotracheal nebulization every 12 hours for a maximum of 7 days using an Aeroneb Solo nebulizer.
Reconstituted solnatide as well as placebo solution (saline) will be supplied in a closed and labelled syringe to study personnel authorized for administration. Both solutions are clear and colorless, and thus indistinguishable in appearance.
Dosing and Administration
In this dose ascending study, 3 groups of patients (one for each dosage) will be randomized to treatment with either solnatide or placebo. The three doses administered in this study are 5 mg, 60 mg and 125 mg and escalation from one dose to the next will occur only once a DSMB has carefully reviewed the safety data emerging from the last treatment group and has approved the administration of the next highest dosage. The highest dosage used in this study has already been tested and has proved to be safe in a Phase I and two Phase II trials and no dose-limiting effects are expected.
Patients will be treated with solnatide or placebo twice a day for seven days via endotracheal inhalation. Inhalations should be scheduled around 08:00 a.m. (+/- 30 minutes) and 08:00 p.m. (+/- 30 minutes). The 12-hour sequence should be followed as closely as possible. If applicable to the routine of the ICU, inhalation can be shifted to a later time until 10:00 a.m. (+/- 30 minutes) and 10:00 p.m. (+/- 30 minutes), respectively, at the latest.
To enable endotracheal inhalation, reconstituted solnatide in water for injection is converted into an inhalable aerosol by the Aeroneb Solo medicinal device. This device is a product of Aerogen, Galway, Ireland and is a commercially available liquid nebulizer. The Aerogen Solo nebulizer has been approved in the European Community by CE-marking based on requirements of Annex II, Section 3.2. of Directive 93/42/EEC.
The nebulizer unit holds up to 6 ml of liquid medication. The nebulizer unit is clear to allow visual monitoring of medication levels and aerosolization. When the nebulizer unit is connected to the ventilator circuit, the silicon plug can be opened and closed in between doses without causing loss of circuit pressure.
The T-piece of the nebulizer connects the unit into the breathing circuit via standard male and female 22 mm conical ports. The nebulizer unit together with the T-piece is placed into the inspiratory limb of the breathing circuit before the patient wye. Various in vitro studies and laboratory simulation have been conducted to characterize solnatide aerosol generation by the Aeroneb Solo nebulizer. Solnatide solution of 25 mg/ml showed effective nebulization and small condensation losses of solnatide aerosol in the connecting tube system. The nebulization time for 5 ml ranges between 10 and 20 minutes. Breath simulator studies showed that approx. 60% to 70% of nebulized solnatide was deposited on the inhalation filter (“lung”), indicating that the delivered dose of solnatide corresponds to about 60% to 70% of the nominal nebulizer filling dose.
Criteria for discontinuing or modifying allocated interventions {11b}
Discontinuation from treatment does not mean discontinuation from the study, and remaining study procedures should be completed as indicated by the study protocol as described for any treatment day as well as follow-up period. If a clinically significant finding is identified (including, but not limited to changes from baseline) after enrolment, the investigator or qualified designee will determine if any change in participant management is needed. Any new clinically relevant finding will be reported as an adverse event (AE).
Every subject, the legal representative or authorized representative has the right to interrupt or to discontinue study participation at any time, for any reason, and every subject may be discontinued from the study for any reason beneficial to his/her wellbeing.
In addition, individual subjects must discontinue or withdraw from the study for any of the following reasons:
- Withdrawal of informed consent by the patient or the legal representative or authorized representative.
- Any AE, laboratory abnormality or intercurrent illness that, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the subject.
- Suspected drug related serious adverse event (SAE)
- Suspected unexpected serious adverse reaction (SUSAR)
- Allergies or idiosyncrasies to solnatide.
Patients withdrawn from the study will not be replaced with new participants.
If the cause of temporary withdrawal has been resolved, e.g. Informed Consent has been re-confirmed, a suspected drug related SAE has not been confirmed by the Investigator, a SUSAR has not been confirmed by the Investigator, the patient may resume participation in the clinical study if the treatment schedule allows it.
Patients who are withdrawn from the study prematurely by the investigator or the sponsor will undergo all investigations as described for any treatment day for the end-of-study interview. Patients, the legal representative or authorized representative who withdraw consent will be asked to accept further safety examinations in the interest of the patient.
Strategies to improve adherence to interventions {11c}
The study medication will be administered only by authorized study personnel. Every effort will be made to ensure timely administration of the IMP as per protocol. If medication cannot be administered, the reason is to be documented in the eCRF and a protocol deviation recorded.
Relevant concomitant care permitted or prohibited during the trial {11d}
There are no known interactions of solnatide with other substances. Accordingly, a general list of permitted and not-permitted concomitant medication is not available. In previous clinical studies no drug- related SAEs and SUSARs have been observed.
As this is an add-on study in patients also receiving standard treatment, administration of concomitant medication is subject to the Investigator’s decision and discretion and may vary for each individual patient due to the heterogeneity of ARDS and underlying etiologies.
Provisions for post-trial care {30}
Specific post-trial care is not provided. Study participants are insured against any harm arising from the study interventions according to legal provisions.
Outcomes {12}
The main objective of this study is to investigate the safety of solnatide administration. Therefore, no formal primary and secondary outcomes are defined. Safety will be assessed by a review of mortality, incidence of adverse events and serious adverse events, as well as by analysis of relevant laboratory data and ECG. The following parameters will be taken into account when assessing the safety of solnatide:
- vital signs (i.e. heart rate, systolic and diastolic blood pressure, and temperature)
- clinical laboratory (i.e. white and red blood cell count, hematocrit, hemoglobin concentration, platelet count, creatinine, sodium, potassium, chloride, blood urea nitrogen, bilirubin, aspartate and alanine transaminases, lactate dehydrogenase, amylase, lipase, C-reactive protein, creatine kinase, arterial pH, PaO2, PaCO2, bicarbonate, SO2 as well as urine pH, specific weight, appearance, color, nitrites, proteins, glucose, urobilinogen, bilirubin, ketones, hematic pigments, and leukocytes)
- 12-lead electrocardiogram
- hemodynamic parameters (i.e. mean arterial pressure, pulmonary blood volume, cardiac index, and cardiac output
- need for vasoactive drugs
- 24-hour fluid balance
- concomitant medications
- all-cause deaths
- utilization of extra-corporeal treatments
- adverse events and serious adverse events
The secondary objective of this study is to evaluate possible endpoints for a future phase III pivotal trial. Such endpoints investigated in this study include:
- extra-vascular lung water index
- pulmonary vascular permeability index
- Murray lung injury score
- oxygenation ratio
- ventilation parameters (i.e. plateau pressure, tidal volume, positive end-expiratory pressure, peak inspiratory pressure, respiratory rate, FiO2, mean airway pressure, peak airway pressure, ventilation mode)
- lung compliance
- ventilation free days
- days of ICU
- days of hospitalization
- driving pressure
- sequential organ failure assessment
Participant timeline {13}
The intended timeline for each participant’s study activities is outlined in fig. 1.
Sample size {14}
Given that the primary objective of the study is to investigate the safety of solnatide, the study sample size of 80 randomized patients is based on feasibility criteria.
Patients will be randomized to 4 groups of 20 patients each, consisting of 3 multiple ascending dose groups receiving solnatide at doses of 5 mg, 60 mg and 125 mg and 1 group receiving placebo.
Nevertheless, considering the key preliminary efficacy endpoint and the results of a phase IIa study (2012-001863-64), a sample size of 20 evaluable patients in each treatment group will have approximately 80% power to detect a difference in means between solnatide and placebo of 3.2 ml/kg in the change from baseline to day 7 of EVLWI with a common SD of 3.5 using a two-group t-test with a 0.05 two-sided significance level and no alpha level adjustment for multiple testing.
Recruitment {15}
Not applicable.
Assignment of interventions: allocation
Sequence generation {16a}, Concealment mechanism {16b}
and Implementation {16c}
A randomization plan will be generated before study start. No stratification factors are planned. Three different randomization lists (one for each step of the study) will be prepared with the following randomization ratios:
- 2:1 in the first step of solnatide 5 mg vs. placebo
- 4:1 in the second step of solnatide 60 mg vs. placebo
- 4:1 in the third step of solnatide 125 mg vs. placebo
The randomization process will be managed electronically by means of an Interactive Web Response System (IWRS) to ensure that treatment assignment is unbiased and concealed from patients and investigator staff.
Assignment of interventions: Blinding
Who will be blinded {17a}
This is a double-blind study. Patients and all clinical team members involved in the study are blinded. Solnatide and saline solution have the same appearance. All personnel except pharmacy staff directly involved in the study, including the Investigator, are blinded to the medication codes.
Pharmacy staff in charge of labelling and preparing the IMP will be unblinded. As soon as a patient is randomized, an email will automatically be sent to the pharmacist instructing him or her to prepare a solnatide or saline (placebo) solution for that randomization number. The syringe containing 5 ml of either one or the other solution will be appropriately labelled and delivered to the ICU for administration. The pharmacist will then print and sign the email for filing purposes. No clinical staff member has access to the treatment preparation instructions except for the study pharmacists.
Procedure for unblinding if needed {17b}
Individual patient unblinding during the trial may occur in case of patient emergencies or medically important adverse events including cases of COVID-19.
The code breaking procedure is managed by means of an on-line specific utility implemented in the eCRF and is available for the Investigator and Pharmacovigilance staff only. Sealed envelopes will also be provided as back-up in the unlikely case of system unavailability.
If during the study the Investigator needs to break a code (for emergency reasons), he/she has to follow the procedure implemented in the system clicking on ad hoc icon present on the toolbar.
In case of an individual patient unblinding an automatic email will be sent to the study team notifying the occurrence of a code break reminding the Investigator to discontinue the patient from the study.
Data collection and management
Plans for assessment and collection of outcomes {18a}
All data collected for this trial, e.g. eligibility criteria, demography, medical history, concomitant medication, physical examinations, vital sign measurements, laboratory results, ECG data, is first recorded in site specific clinical charts based either on electronic or paper documents. If electronic charts are used, the electronic system should be compliant with applicable requirements. No study related information will be stored on the eCRF only.
For laboratory tests, each site uses its own certified routine laboratory, which also provides its own reference values for each parameter obtained for study purposes. Measurements like ECG or hemodynamic parameters will be obtained using medical-grade, certified equipment.
Clinical scores are assessed based on the following resources:
- Gas Exchange, Organ Failure, Cause Associated Disease (GOCA) Score (25,26)
- Sequential Organ Failure Assessment (SOFA) (27)
- Acute Physiology and Chronic Health Evaluation (APACHE) II Score (28)
- Simplified Acute Physiology Score (SAPS) 3 (29,30)
Plans to promote participant retention and complete follow-up {18b}
Not applicable as this is a study of patients with ARDS in intensive care and under mechanical ventilation.
Data management {19}
Designated investigator staff will enter the data required by the protocol into the eCRF using fully validated software that conforms to 21 CFR Part 11 requirements as well as GAMP 5 and PIC/S requirements. Designated investigator site staff will not be given access to the Electronic Data Capture (EDC) system until they are trained.
Web-based software will be used and no installation procedure is needed. Each site will be authorized by the administrator to access the eCRF. Each site-qualified personnel will be allowed to access the eCRF by means of a ‘login mask’ requiring user ID and password and may read, modify, and update only the information he/she previously reported. Each page reports site code and subject code.
Online validation programs will check for data discrepancies and, by generating appropriate error messages, allow the data to be confirmed or corrected before transfer to the CRO working on behalf of the sponsor. The investigator will certify that the data entered into the eCRF is complete and accurate.
After database lock, the investigator will receive a CD-ROM of subject data for archiving at the investigational site.
Confidentiality {27}
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.
All research activities will be conducted in as private a setting as possible.
The study monitor, other authorized representatives of the sponsor, representatives of the IRB/IEC, regulatory agencies or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.
The study participant’s contact information will be securely stored at each clinical site for internal use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the reviewing IRB/IEC, Institutional policies, or sponsor requirements.
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be collected and stored at the OPIS Data Center. This will not include the participant’s contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by OPIS Data Center staff will be secured and password protected.
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
Not applicable
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
Data collected in this study will be listed and summarized as described below by treatment group. Data from all sites will be pooled and summarized. Continuous data will be summarized by mean, standard deviation (SD), median, first and third quartiles, minimum and maximum. Categorical data will be presented by absolute and relative frequencies (n and %) or contingency tables. All statistical tables, listings, figures and analyses will be performed by means of SAS® release 9.4 or later (SAS Institute, Inc., Cary, NC, USA).
A two-sided alpha level 0.05 will be considered. No alpha level adjustment will be made for secondary preliminary efficacy outcome variables and for multiple comparisons. Patients will be included in each analysis based on available assessments. No methodology for missing data handling will be applied, except for the EVLWI efficacy endpoint. Censoring rules for time-to-event analyses will be detailed in the Statistical Analysis Plan.
There is no primary efficacy endpoint as the primary objective of the study is to investigate the safety of solnatide. All efficacy analysis will be considered as secondary preliminary efficacy analyses. All secondary preliminary efficacy analyses will be performed based on the ITT set as primary analysis and on the PP set as supportive analysis and will be reported by planned treatment cohort.
No methodology for missing data handling will be applied for secondary preliminary efficacy endpoints, except for EVLWI. The homogeneity of treatment effects across different centers will not be tested.
Change from baseline to day 7 in extravascular lung water index (EVLWI)
The absolute change from baseline in extravascular lung water index (EVLWI) after 7 days from randomization, as assessed with a validated bedside measurement (single indicator transpulmonary thermodilution measurement, such as with PiCCO® from Pulsion or VolumeView from Edwards), will be analyzed by means of an analysis of covariance (ANCOVA) model with baseline value as covariate and treatment cohort as an independent class variable. Mean estimates will be provided, together with their corresponding two-sided 95% confidence intervals.
A hierarchical testing procedure will be carried out to control multiplicity, where statistical comparison will first be performed between the highest solnatide dose cohort and the placebo cohort. Statistical comparison between the next lower dose(s) and placebo will be performed only in case of statistical significance of the comparison between the highest solnatide dose cohort and the placebo cohort.
The analysis described above will be performed on data where the Last Observation Carry Forward approach is applied for handling missing data. Additional imputation methodologies for missing data may be applied as sensitivity analysis (further details to be provided in the Statistical Analysis Plan).
1. Secondary preliminary efficacy Endpoints
Change from baseline to day 7 in Pulmonary Vascular Permeability Index (PVPI)
The absolute value and the change from baseline will be analyzed by treatment group for PVPI by means of summary descriptive statistics at each time point until day 7.
Lung compliance during mechanical ventilation
Static lung compliance is the change in volume for any given applied pressure and is derived as the ratio between tidal volume (Vt) and the difference between plateau pressure and positive end-expiratory pressure (PEEP).
The absolute value and the change from baseline will be analyzed for static lung compliance by means of summary descriptive statistics at each time point through day 14, if patient is mechanically ventilated (controlled mechanical ventilation).
Murray lung injury score (LIS)
The absolute value and the change from baseline will be analyzed for Murray Lung Injury Score by means of summary descriptive statistics at each time point until day 7 if chest x-ray is available.
Sequential Organ Failure Assessment (SOFA)
The absolute value and the change from baseline will be analyzed for SOFA score by means of summary descriptive statistics at each time point until day 7.
Oxygenation ratio (PaO2/FiO2 ratio)
The absolute value and the change from baseline will be analyzed for Oxygenation ratio (PaO2/FiO2) by means of summary descriptive statistics at each time point during first 7 days.
Ventilation parameters
The absolute value and the change from baseline will be analyzed for each ventilation parameter (ventilatory plateau pressure, Vt, PEEP, respiratory rate, FiO2, PIP, mean airway pressure, peak airway pressure) by means of summary descriptive statistics at each time point through Day 14 for patients mechanically ventilated (controlled mechanical ventilation, assisted breathing, non-invasive ventilation).
Driving pressure (Pplat -PEEP)
The absolute value and the change from baseline will be analyzed for driving pressure (Pplat – PEEP) by means of summary descriptive statistics at each time point through Day 14 for patients mechanically ventilated (controlled mechanical ventilation, assisted breathing, non-invasive ventilation).
Spontaneous Breathing Trial
The time (in days) from the first spontaneous breathing trial to the first successful extubation / unassisted breathing will be calculated. Summary descriptive statistics will be provided.
In addition, patients will be classified according to the following outcome definitions (31):
- Simple
- Successful SBT after the first attempt
- Difficult
- Failed SBT at first attempt and
- Required up to three trials or
- Required <7 days to reach successful SBT
- Prolonged
- Required >7 days to reach successful SBT
Time to extubation through day 28
Time to extubation (in days) is defined as the difference between the first extubation date and the randomization date. Patients still intubated at day 28 or who die while still intubated will be censored at day 28. Summary descriptive statistics will be provided for the time to extubation.
Ventilator-free days (VFD) through day 28
VFD is defined as the number of days from randomization to day 28 after achieving unassisted breathing for patients who maintained unassisted breathing for at least two consecutive calendar days. If a patient survived for more than 48 consecutive hours of unassisted breathing but required assisted breathing (for any reason) before day 28, the number of VFD is the number of days of successful unassisted breathing through day 28. All periods of successful unassisted breathing (> 48 consecutive hours) are taken into account. Unassisted breathing is defined as being extubated with face mask, with nasal prong oxygen or room air or T-tube breathing or tracheostomy mask breathing or CPAP breathing with ≤8 cm H20 pressure support of assisted ventilator support, according to weaning protocol. Patients who die before Day 28 will be assigned the number of days of successful unassisted breathing. If a patient required more than 28 days of mechanical ventilation, the value for VFD will be set to 0.
The parameter of ventilator-free days will be analyzed by means of an analysis of variance (ANOVA) model with treatment cohort as an independent class variable. Mean estimates will be provided, together with their corresponding two-sided 95% confidence intervals.
No multiplicity adjustment for multiple comparison will be applied, given that statistical comparison will be performed only between the highest solnatide dose cohort and the placebo cohort. A statistical comparison between lower dose(s) and placebo will be performed only in case of statistical significance of the comparison between the highest solnatide dose cohort and the placebo cohort.
Days of hospitalization through day 28
Length of hospital stay (in days) is defined as the difference between the discharge date and the randomization date. Patients still in the hospital at day 28 or who die during hospitalization will be censored at day 28. Days of outpatient hospitalization will not be included. Summary descriptive statistics will be provided for the number of days of hospitalization.
Days of stay at ICU through day 28
Length of stay at ICU (in days) is defined as the number of calendar days a patient was in the ICU. Patients still in the ICU at day 28 or who die during the stay at ICU will be censored at day 28. Summary descriptive statistics will be provided for the number of days of stay at the ICU.
2. Safety analyses
Safety analyses will be conducted on the Safety Set and will be reported by actual treatment cohort. No methodology for missing data handling will be applied for safety parameters.
Drug related adverse events through day 14
The incidence of treatment-emergent drug related AEs through day 14 after randomization, both in terms of number of events and in terms of patients with at least one event, will be tabulated by MedDRA System Organ Class (SOC) and Preferred Term (PT).
All adverse events through day 28
According to the onset date of the event, AEs will be defined as follows:
- treatment-emergent AEs are those events with an onset date after treatment initiation;
- non-treatment-emergent AEs are those events with an onset date between screening and treatment initiation.
Non-treatment-emergent adverse events will be listed only. The incidence of treatment-emergent adverse events (TEAE) will be tabulated by MedDRA System Organ Class (SOC) and Preferred Term (PT). The incidence of TEAEs will also be summarized by system organ class, preferred term and severity (based on investigator’s judgment).
The same analysis will be repeated for SAEs regardless of drug relationship, for drug related SAEs, AEs with an outcome of death and AEs leading to discontinuation of treatment. Deaths reportable as SAEs will be listed by patient and tabulated by MedDRA SOC and PT.
All-cause deaths through day 28
The number and proportion of deceased patients will be reported. In addition, the time (in days) from randomization to the event will be used for analysis. Subjects without an event will be censored at the earlier of the last contact date or Day 28. The Kaplan-Meier estimates of the survival functions for each treatment cohort will be plotted and summarized.
Vital signs
The absolute value and the change from baseline will be analyzed for each parameter (including heart rate, systolic and diastolic blood pressure and body temperature) by means of summary descriptive statistics at each time point through day 14 after randomization.
ECG parameters
Evaluation of ECG data will be performed by an external provider.
The absolute value and the change from baseline will be analyzed for each cardiac parameter (PQ, QRS, QT and QTc intervals [Fridericia’s formula] and heart rate) by means of summary descriptive statistics at each time point (first 7 days of study). Based upon these parameters heart rhythm anomalies / conduction abnormalities as well as changes/abnormalities in ECG morphology will be assessed and summarized.
Laboratory parameters
The absolute value and the change from baseline will be analyzed for each laboratory parameter (separately for hematology, clinical chemistry, blood gases, and urinalysis) by means of summary descriptive statistics at each time point through day 14. In addition, shift tables using the low/normal/high classification according to the laboratory normal ranges to compare baseline to the worst on-treatment value will be provided.
Listings of all laboratory data with values flagged to show the classifications relative to the laboratory normal ranges will also be generated.
24-hour fluid balance
The absolute value and the change from baseline will be analyzed for the 24-hour fluid balance parameter by means of summary descriptive statistics at each time point through day 7. 24-hours fluid balance at a given timepoint will be determined as the difference, at the timepoint, between the complete amount of fluid supplied to the patient over 24 hours and the complete amount of fluid lost by the patient over the same period.
Hemodynamic parameters
The absolute value and the change from baseline will be analyzed for each hemodynamic parameter (i.e. mean arterial pressure, pulmonary blood volume (PBV), cardiac index and cardiac output) by means of summary descriptive statistics at each time point until the end of treatment.
Need for vasoactive drugs
The number and proportion of patients who required vasoactive drugs at any time through the end of treatment will be reported.
3. Baseline descriptive statistics
Patient demographics and baseline characteristics will be summarized on the ITT set, overall and by treatment cohort, by means of summary descriptive statistics. A complete description of subject disposition will be provided, overall and by treatment cohort specifying the number of randomized subjects, number of subjects at each visit, and completed and discontinued subjects and the reason for the discontinuation. The analysis populations will be described and the reasons for excluding the subject from any analysis set will be provided with the number of protocol violators per each criterion. Medical history data will be presented by MedDRA System Organ Class and Preferred Term.
4. Treatments
The Safety set will be used for the following analyses.
Investigational treatment
Duration of exposure to study treatment, defined as the time (days) elapsed from the date of the first treatment administration to the date of the last treatment administration and number of administrations will be summarized. Cumulative dose (mg), defined as the total dose given during treatment exposure, will be summarized. The number of patients with dose interruptions/permanent discontinuation will be presented along with the reasons for the dose interruptions/discontinuation.
Concomitant treatments
Concomitant medications or procedures taken concurrently with the study treatment will be listed and summarized by WHO Anatomical Therapeutic Chemical (ATC) Class and Preferred Term. These summaries will include medications starting on or after the start of study treatment, or medications starting prior to the start of study treatment and continuing after the start of study treatment. Prior medications starting and ending prior to the start of study treatment will be listed only.
Interim analyses {21b}
No formal interim efficacy analysis is planned.
Methods for additional analyses (e.g. subgroup analyses) {20b}
Additional sub-group analyses will be detailed in the Statistical Analysis Plan.
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}
Patients will be included in each analysis based on available assessments. No methodology for missing data handling will be applied, except for the EVLWI efficacy endpoint.
Plans to give access to the full protocol, participant level-data and statistical code {31c}
Not applicable
Oversight and monitoring
Composition of the coordinating center and trial steering committee {5d}
The clinical study is coordinated by a professional Clinical Research Organization (CRO). The CRO and the sponsor form the trial steering committee.
The data management is part of the responsibility of the CRO and cannot accessed by the sonsor. No unblinded data are submitted from the data management to the sponsor and to the investigators.
There is no endpoint adjudication committee foreseen.
Composition of the data monitoring committee, its role and reporting structure {21a}
The sponsor has appointed an independent Data and Safety Monitoring Board. The DSMB’s role is defined in the DSMB Charter of clinical trial EudraCT 2017-003855-47 of March 2018. The DSMB is composed of individual experts in the field of ARDS from following countries: Germany, Spain, USA. All members of the DSMB have no competing interest in the trial.
The DSMB is responsible for reviewing the safety and tolerability after completion of each dose group and confirmation in writing that the study can proceed with the next higher dose group (dose escalation). After completion of the study the DSMB will make a final statement concerning overall safety (the primary objective of the study). Overall safety will be assessed in a final session of the DSMB by a summarizing review of the incidence of mortality, adverse events, and serious adverse events, as well as by analysis of relevant laboratory data and ECG's. The DSMB will provide advice to the Sponsor which will be responsible for promptly reviewing the DSMB recommendations, deciding whether to continue, modify or terminate the trial; and determining whether amendments to the protocol or changes in study conduct are required.
The DSMB is required to act in accordance with the ethical principles derived from the Declaration of Helsinki.
Communication with DSMB members will be primarily through an independent statistician not involved in the management and performance of this study. It is not expected that study investigators or co-investigators will directly communicate with DSMB members.
Adverse event reporting and harms {22}
All identified non-serious AEs (related and unrelated) must be recorded and described on the non-serious AE page of the eCRF.
Serious adverse event reporting
Every SAE, regardless of suspected causality, occurring after screening and until at least 28 days after randomization must be reported to the sponsor within 24 hours of site awareness. Any SAE experienced after this 28-day period should only be reported to the sponsor if the investigator suspects a causal relationship to the study treatment. Recurrent episodes, complications, or progression of the initial SAE must be reported as follow-up to the original episode within 24 hours of the investigator receiving the follow-up information. Information about all SAEs will be recorded on the AE page of the eCRF and transmitted through the SAE tool. In case of technical difficulties, SAE notification can be carried out by sending a paper SAE form to the Pharmacovigilance Officer via email or by fax.
All SAEs still ongoing at end of study will be followed up by means of queries requesting updates. Other supporting documentation of the event may be requested by the study sponsor and should be provided as soon as possible. The study sponsor will be responsible for notifying Health Authorities of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 calendar days after the sponsor's initial receipt of the information.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries.
Reporting events to participants
Should an event occur that changes the overall benefit/risk ratio of the study, the Sponsor shall evaluate if a risk minimization measure is needed. Should this measure require a substantial amendment to the protocol, the informed consent and patient information will be revised and submitted to the patient for written consent.
Frequency and plans for auditing trial conduct {23}
Clinical site monitoring will be conducted to ensure that the rights and well-being of human subjects are protected, that the reported study data are accurate, complete, and verifiable, and that the conduct of the study complies with the currently approved protocol, with Good Clinical Practice (GCP), and with applicable regulatory requirements. Monitoring for this study will be performed by a Contract Research Organization (CRO), OPIS. Details of clinical site monitoring are documented in a Monitoring Plan (MP). The MP describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports.
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}
Important protocol modifications will be reported to the responsible ethics committees and, after approval, made accessible to the study centers. As far as the ICF is subject to any revision, all future participants will be provided with an updated version of the ICF. Protocol amendments will not be communicated to past participants.
Dissemination plans {31a}
This study will ensure that the public has access to the published results of the research. The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. Health outcomes include any biomedical or health-related measures obtained in patients or subjects, including pharmacokinetic measures and adverse events. The ICMJE policy requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine. Other biomedical journals are considering adopting similar policies.